Novo Nordisk’s India Experiment Offers Hope as Pipeline Retrenches

India sales of Novo's branded semaglutide drugs jumped 40% after patent expiry, as generics expanded the market. Meanwhile, pipeline setbacks include a heart failure miss and licensing out of a Parkinson's therapy.

Novo Nordisk’s first real-world showdown with generic competition is producing the kind of numbers that make investors sit up. Sales of Ozempic and Wegovy in India jumped 40% in April to 32,000 units, the first full month since patent protection on semaglutide lapsed. The Danish drugmaker slashed starter-dose prices by 36% and 48% respectively from 1 April, bringing the entry therapy to around $60. Far from being crushed by cheaper copies, the branded pair gained ground.

The broader Indian market for semaglutide-based products expanded even faster. Total volumes, including generics from Sun Pharma, Dr. Reddy’s, Zydus Lifesciences and Glenmark, rose 56% to 414,000 units in April, according to market researcher Pharmarack. “Generics have so far expanded the market rather than massively eroded the originator share,” said Sheetal Sapale of Pharmarack. That dynamic is critical for Novo as it navigates a global patent cliff: the US market is shielded until December 2031 by extensions, but Canada has already cleared generics (commercial launch pending) and China’s generic Ozempic rollout is expected only next year.

Novo’s distribution strategy in India relies on partners with deep pharmacy and doctor networks – Emcure Pharma for Wegovy (sold as Poviztra) and Abbott India for Ozempic (sold as Extensior). That local footprint, combined with aggressive pricing, is proving resilient. The company’s 2026 guidance now calls for a currency-adjusted revenue and operating profit decline of 4% to 12%, an improvement from the previous 5% to 13% range.

While India delivers a tactical win, the pipeline is undergoing a sobering recalibration. Novo this week licensed out STEM-PD, an allogeneic stem cell therapy for Parkinson’s disease, to the AI-focused biotech Cellular Intelligence, which counts the Chan Zuckerberg Initiative among its backers. No upfront payment is involved; Novo receives potential milestones, royalties and an equity stake in the firm. The move follows the closure of its cell therapy unit in October 2025 and the elimination of roughly 250 positions. STEM-PD will now advance outside Novo’s own research structure, with a next clinical study expected to begin in late 2026 or early 2027.

Harder to outsource is the disappointment in heart failure. The microRNA drug CDR132L (internal code NN6706), acquired through the 2024 purchase of Cardior Pharmaceuticals for over $1 billion, missed its primary endpoint in the HF-REVERT phase 2 trial. The study of 280 patients with heart failure and reduced ejection fraction met safety and tolerability targets, but improvement in left ventricular stroke volume index was not statistically significant – a roughly 10% gain at the highest dose versus about 7% for placebo. Two other phase 2 studies are still running, with results due in 2027.

The stock has recovered some poise during the past month. The B-share closed at 290.3 Danish kroner in Copenhagen on 11 May, with the ADR equivalent at €39.92 on Monday – a 2.32% gain on the day and a month-on-month rise of 24.47%. Yet the shares remain in the red year-to-date and over twelve months. Analysts are split: Citi lifted its target from 275 to 290 kroner but rates the stock “neutral”, while SB1 Markets went to 350 kroner with a buy recommendation.

Momentum is coming from the US, where the Wegovy pill has racked up more than 2 million prescriptions since January 2026. Chief executive Mike Doustdar pointed to double-digit growth for the tablet and a 65% share of new prescription starts for the Wegovy brand. Novo has also edged up its full-year outlook, even as it concedes an overall revenue decline.

For a company built on obesity and diabetes blockbusters, the next big calls are a long way from the corporate laboratory. India shows that branded drugs can still grow even when generics arrive. The real tests come in Canada and China, and with the Parkinson therapy now in outside hands, investors will be watching whether the cell-therapy retreat and heart failure letdown signal a more selective approach – or a pipeline that is running out of easy hits.